The Antifungal Drug ----- Efluconazole

The Antifungal Drug -----  Efluconazole

Efinaconzole is a small molecule triazole antifungal drug developed by Kaken Pharmaceutical Co. Approved for marketing in Canada and the U.S. in October 2013 and June 2014, respectively, for the treatment of gray nails of the toes, the drug is the first topical triazole antifungal drug to be marketed.

Formulated as a topical solution that is applied via a unique built-in dose-controlled nail brush, the drug dries quickly without removing an overdose and without concern for systemic side effects, such as drug interactions or acute liver injury.

Clinical Applications

Efluconazole is the first topical triazole antifungal agent developed for the treatment of localized distal lateral subluxation nail fungus (DLSO), the most common form of nail fungal disease in which the causative organism first invades the distal subluxation nail bed, causing hyperkeratosis and thickening of the subluxation nail bed, which can turn the nail plate white, brown to grayish-brown, with an uneven surface, loss of luster, and missing, brittle nail plates. Applied by a unique built-in dosage control nail brush, the drug dries quickly without the need to go out and overdose and without concern for systemic side effects such as drug interactions or acute liver damage.

Efluconazole is a broad-spectrum antifungal drug commonly used to treat fungal skin infections, oral and throat fungal infections, and vaginal fungal infections. It exerts its antifungal action by inhibiting the synthesis of fungal cell membranes. Efluconazole can be administered orally, topically or by injection. Common side effects include headache, nausea, vomiting, diarrhea, rash, etc. Medical advice should be followed when using it to avoid overdose or long-term use.